
Vincenzo Messina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7814506/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?. Diabetes Care, 2020, 43, 1408-1415.	4.3	341
2	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. Journal of Hepatology, 2012, 56, 1006-1011.	1.8	155
3	HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology, 2002, 36, 1285-1291.	3.6	122
4	Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut, 2013, 62, 290-298.	6.1	105
5	Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Diabetes and Metabolism, 2020, 46, 403-405.	1.4	105
6	The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases. Journal of Medical Virology, 2005, 75, 522-527.	2.5	102
7	HBV superinfection in HCV chronic carriers: A disease that is frequently severe but associated with the eradication of HCV. Hepatology, 2009, 49, 1090-1097.	3.6	94
8	Does poor glycaemic control affect the immunogenicity of the <scp>COVIDâ€19</scp> vaccination in patients with type <scp>2</scp> diabetes: The <scp>CAVEAT</scp> study. Diabetes, Obesity and Metabolism, 2022, 24, 160-165.	2.2	75
9	Hyperglycaemia on admission to hospital and COVID-19. Diabetologia, 2020, 63, 2486-2487.	2.9	72
10	Liver microRNA hsa-miR-125a-5p in HBV Chronic Infection: Correlation with HBV Replication and Disease Progression. PLoS ONE, 2013, 8, e65336.	1.1	72
11	Could Antiâ€Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVIDâ€19 Infection? Data From Centers of Southern Italy. Journal of the American Heart Association, 2020, 9, e016948.	1.6	69
12	Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. Journal of Medical Virology, 2011, 83, 1909-1916.	2.5	64
13	Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: A multicenter study. Journal of Medical Virology, 2008, 80, 1547-1553.	2.5	63
14	The epidemiology of hepatitis delta infection in Italy. Journal of Hepatology, 1992, 15, 211-215.	1.8	62
15	Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study. Journal of Medical Virology, 2009, 81, 1999-2006.	2.5	61
16	Chronic Hepatitis B in Italy: New Features of an Old Disease-Approaching the Universal Prevalence of Hepatitis B e AntigenNegative Cases and the Eradication of Hepatitis D Infection. Clinical Infectious Diseases, 2008, 46, 110-113.	2.9	60
17	Treatment of chronic hepatitis B: Recommendations from an Italian workshop. Digestive and Liver Disease, 2008, 40, 603-617.	0.4	50
18	Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis. Journal of Viral Hepatitis, 2000, 7, 30-35.	1.0	47

VINCENZO MESSINA

#	Article	IF	CITATIONS
19	Clinical Presentation, Outcome, and Response to Therapy Among Patients With Acute Exacerbation of Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 1174-1180.e11.	2.4	47
20	Implications of AB0 blood group in hypertensive patients with covid-19. BMC Cardiovascular Disorders, 2020, 20, 373.	0.7	46
21	Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. Journal of Clinical Virology, 2009, 46, 222-229.	1.6	42
22	Anti-HCV IgG avidity index in acute hepatitis C. Journal of Clinical Virology, 2007, 40, 110-115.	1.6	40
23	Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology, 2014, 59, 2101-2109.	3.6	38
24	Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. Nature Communications, 2022, 13, 2318.	5.8	33
25	Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. Journal of Hepatology, 2005, 42, 646-651.	1.8	32
26	Realâ€life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. Liver International, 2019, 39, 1852-1859.	1.9	31
27	Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. Journal of Viral Hepatitis, 2009, 17, 493-500.	1.0	30
28	Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. Journal of Infection, 2013, 67, 322-328.	1.7	26
29	The aetiology of chronic hepatitis in Italy: results from a multicentre national study. Digestive and Liver Disease, 2004, 36, 829-833.	0.4	24
30	HCV infection is a risk factor for gallstone disease in liver cirrhosis: an Italian epidemiological survey. Journal of Viral Hepatitis, 2007, 14, 618-623.	1.0	24
31	Clinical and virological characteristics associated with severe acute hepatitis B. Clinical Microbiology and Infection, 2014, 20, 0991-0997.	2.8	23
32	Autonomic nervous system and lipid metabolism: findings in anxious-depressive spectrum and eating disorders. Lipids in Health and Disease, 2011, 10, 192.	1.2	22
33	More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study. Frontiers in Oncology, 2021, 11, 662746.	1.3	21
34	Antiarrhythmic Drug Therapy after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2007, 30, S112-5.	0.5	20
35	HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study. Digestive and Liver Disease, 2017, 49, 1022-1028.	0.4	19
36	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1123-1130.	1.4	18

#	Article	IF	CITATIONS
37	Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti–HepatitisÂC Virus Positive Patients: The Need toÂControlÂHepatitis BÂVirus Replication to Avoid Hepatitis BÂVirusÂReactivation. Clinical Gastroenterology and Hepatology, 2017, 15, 1800-1802.	2.4	17
38	Tolerability and efficacy of antiâ€HBV nucleos(t)ide analogues in HBVâ€DNAâ€positive cirrhotic patients with HBV/HCV dual infection. Journal of Viral Hepatitis, 2012, 19, 890-896.	1.0	15
39	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15
40	Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6 999 cases. Journal of Viral Hepatitis, 2006, 13, 351-354.	1.0	14
41	Virological patterns of HCV patients with failure to interferonâ€free regimens. Journal of Medical Virology, 2018, 90, 942-950.	2.5	14
42	Innovative procedures for microâ€elimination of HCV infection in persons who use drugs. Journal of Viral Hepatitis, 2020, 27, 1437-1443.	1.0	14
43	Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A realâ€ife study. Liver International, 2017, 37, 653-661.	1.9	13
44	Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. Infection, 2018, 46, 231-238.	2.3	13
45	Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents. European Review for Medical and Pharmacological Sciences, 2020, 24, 5193-5194.	0.5	13
46	Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. Digestive and Liver Disease, 2014, 46, 826-832.	0.4	12
47	ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free Regimens. Antiviral Therapy, 2017, 22, 551-558.	0.6	12
48	A different perspective on sofosbuvirâ€ledipasvir treatment of patients with <scp>HCV</scp> genotype 1b cirrhosis: The ital network study. Journal of Viral Hepatitis, 2018, 25, 56-62.	1.0	11
49	Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 607-614.	1.3	10
50	Factors affecting longâ€ŧerm changes of liver stiffness in directâ€acting antiâ€hepatitis C virus therapy: A multicentre prospective study. Journal of Viral Hepatitis, 2022, 29, 26-34.	1.0	10
51	Correlation Between the Hepatic Expression of Human MicroRNA hsa-miR-125a-5p and the Progression of Fibrosis in Patients With Overt and Occult HBV Infection. Frontiers in Immunology, 2018, 9, 1334.	2.2	9
52	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. Liver International, 2019, 39, 484-493.	1.9	9
53	High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients. Gut and Liver, 2020, 14, 357-367.	1.4	9
54	Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project. Journal of Infection and Public Health, 2022, 15, 562-565.	1.9	8

VINCENZO MESSINA

#	Article	IF	CITATIONS
55	Long-term lymphoblastoid interferon-α therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFNI± treatment. Research in Virology, 1998, 149, 283-291.	0.7	7
56	Long-Term Results of Hybrid Therapy in Patients with Atrial Fibrillation Who Develop Atrial Flutter During Flecainide Infusion. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S124-S127.	0.5	7
57	Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. Annals of Hepatology, 2014, 13, 376-385.	0.6	7
58	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65Âyears with HCV genotype 1 cirrhosis. Infection, 2018, 46, 607-615.	2.3	7
59	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology?. Biology, 2022, 11, 609.	1.3	7
60	Epidemiology and treatment of mood disorders in a day hospital setting from 1996 to 2007: an Italian study. Neuropsychiatric Disease and Treatment, 2013, 9, 169.	1.0	6
61	Hepatitis C Virus Clearance in Older Adults. Journal of the American Geriatrics Society, 2018, 66, 85-91.	1.3	6
62	Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. Life, 2021, 11, 17.	1.1	6
63	Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. Antiviral Therapy, 2019, 24, 485-493.	0.6	5
64	Factors Enhancing Treatment of Hepatitis C Virus–Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. American Journal of Gastroenterology, 2021, 116, 1248-1255.	0.2	5
65	Non responders to interferon therapy among chronic hepatitis patients infected with hepatitis C virus. , 1993, 8, 257-263.		5
66	Abstract 221: Exosomal MicroRNAs Drive Tromboembolism in Covid-19. Circulation, 2020, 142, .	1.6	5
67	Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. World Journal of Hepatology, 2016, 8, 949.	0.8	5
68	Optimization of direct antiâ€viral agent treatment schedule: Focus on HCV genotype 3. United European Gastroenterology Journal, 2018, 6, 225-237.	1.6	4
69	Dangerous liaisons? The role of inflammation and comorbidities in HIV and SARS-CoV-2 infection. Expert Review of Clinical Immunology, 2021, 17, 201-208.	1.3	4
70	Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals. International Journal of Antimicrobial Agents, 2020, 56, 106067.	1.1	3
71	Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2). Anesthesia, Intensive Care and Pain in Neonates and Children, 2020, 8, 9450.	2.4	3
72	Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy. Life, 2021, 11, 347.	1.1	3

#	Article	IF	CITATIONS
73	Efficacy of Unsupervised Self-Collected Mid-Turbinate FLOQSwabs for the Diagnosis of Coronavirus Disease 2019 (COVID-19). Viruses, 2021, 13, 1663.	1.5	3
74	THU-122-Sofosbuvir/velpatasvir ± ribavirin for retreatment of patients with chronic hepatitis C virus infection and advanced fibrosis failing to a previous DAA combination regimen. Journal of Hepatology, 2019, 70, e212-e213.	1.8	1
75	Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life â€~LIver Network Activity' (LINA) cohort update results. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1057-1063.	1.4	1
76	HBV superinfection in HCV chronic carriers. Journal of Hepatology, 2002, 36, 246.	1.8	0
77	THU0289â€PERSISTENCE OF CIRCULATING CRYOGLOBULINS AND RELATED SYMPTOMS AFTER HEPATITIS C VIRUS ERADICATION IN PATIENTS WITH MIXED CRYOGLOBULIN SYNDROME. , 2019, , .		0